Skip to main content
Figure 3 | Journal of Immune Based Therapies and Vaccines

Figure 3

From: Antiviral activity of Engystol® and Gripp-Heel®: an in-vitro assessment

Figure 3

In-vitro type 1 IFN production following Engystol® incubation. Effect of Engystol® on type 1 IFN production in HRV-UV infected HeLa (a) and HSV-UV-co-stimulated PBMCs (b) was determined using IFN-α specific ELISA 5 days after incubation. In figure a data represent mean values ± SD (N = 3). For the PBMC setting 4 different donors were used for each treatment group (first column = donor 1, second column = donor 2, third column = donor 3, fourth column = donor 4).

Back to article page
\